IFRS Statements - Part 1
GlaxoSmithKline PLC
10 February 2005
Issued: 10th February 2005, London
Part 1 of 2
GlaxoSmithKline plc
Financial statements in accordance with
International Financial Reporting Standards
2003 Full year
2004 Quarter 1
2004 Quarter 2
2004 Half-year
2004 Quarter 3
2004 9 months
2004 Quarter 4
2004 Full year
GlaxoSmithKline prepares its financial results in £ sterling.
Accordingly these IFRS Financial statements are prepared in £ sterling.
www.gsk.com
Brand names appearing in italics throughout this document are trade marks of GlaxoSmithKline or associated companies
with the exception of Levitra a trade mark of Bayer which is used under licence by the Group.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions
investors that any forward-looking statements or projections made by the company, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and
Financial Review and Prospects in the company's Annual Report on Form 20-F for 2003.
Table of contents
Page
Basis of preparation .............................................................................................. 4
Income statement
Explanation of IFRS income statement adjustments................................................................... 7
2003 Full year........................................................................................... 9
2004 Quarter 1............................................................................................. 11
2004 Quarter 2............................................................................................. 13
2004 Half-year..............................................................................................15
2004 Quarter 3............................................................................................. 17
2004 9 months.............................................................................................. 19
2004 Quarter 4............................................................................................. 21
2004 Full year............................................................................................. 23
Turnover
Pharmaceuticals
2003 Full year............................................................................................. 26
2004 Quarter 1............................................................................................. 27
2004 Quarter 2............................................................................................. 28
2004 Half-year............................................................................................. 29
2004 Quarter 3............................................................................................. 30
2004 9 months.............................................................................................. 31
2004 Quarter 4............................................................................................. 32
2004 Full year ............................................................................................ 33
Consumer Healthcare
2003 Full year............................................................................................. 34
2004 Quarter 1..............................................................................................34
2004 Quarter 2..............................................................................................34
2004 Half-year..............................................................................................34
2004 Quarter 3 .............................................................................................35
2004 9 months...............................................................................................35
2004 Quarter 4............................................................................................. 35
2004 Full year............................................................................................. 35
Balance sheet
Explanation of IFRS balance sheet adjustments...................................................................... 37
At 31st December 2003.............................................................................................. 39
At 31st March 2004................................................................................................. 41
At 30th June 2004...................................................................................................43
At 30th September 2004............................................................................................. 45
At 31st December 2004.............................................................................................. 47
Table of contents
Page
Cash flow statement
Explanation of IFRS cash flow statement adjustments................................................................. 50
2003 Full year............................................................................................. 51
2004 Quarter 1............................................................................................. 52
2004 Quarter 2............................................................................................. 53
2004 Half-year..............................................................................................54
2004 Quarter 3............................................................................................. 55
2004 9 months.............................................................................................. 56
2004 Quarter 4............................................................................................. 57
2004 Full year............................................................................................. 58
Statement of recognised income and expense
2003 Full year............................................................................................ 60
2004 Full year............................................................................................ 60
Reconciliation of movements in equity
2003 Full year............................................................................................ 61
2004 Full year............................................................................................ 61
Reconciliation by component of equity at 1st January 2003.......................................................... 62
Basis of preparation
Introduction
Following a European Union Regulation issued in 2002, GlaxoSmithKline is moving to reporting its financial
results in accordance with International Financial Reporting Standards (IFRS) from 1st January 2005. This
document presents the unaudited consolidated results of GlaxoSmithKline plc converted from the current UK
Generally Accepted Accounting Principles (UK GAAP) basis onto an IFRS basis for the full years 2003 and 2004 and
for the quarters of 2004. The transition date to IFRS for GlaxoSmithKline is 1st January 2003.
Basis of preparation
This document has been prepared on the basis of all IFRS and Standing Interpretations Committee (SIC) and
International Financial Reporting Interpretations Committee (IFRIC) interpretations issued by the IASB effective
for 2005 reporting. In addition, the IASB issued an amendment to IAS 19, Employee Benefits, in December 2004.
This amendment permits the full recognition of actuarial gains or losses that occur in the year outside the
income statement in a similar way to FRS 17 under UK GAAP. Although not effective until annual periods
beginning on or after 1st January 2006, the amendment may be adopted early. GlaxoSmithKline intends to adopt
this amendment to IAS 19 for 2005 reporting and so the information presented in this document has been prepared
on that basis, which is a change from the basis on which the IFRS information published on 29th October 2004 was
prepared.
The effect of this change is to increase the pension and other post-employment benefit provisions at 31st
December 2003, 31st March 2004 and 30th June 2004 by £435 million, £438 million and £704 million, respectively,
from those presented on 29th October 2004. Consequential adjustments to the deferred tax assets and minority
interests have also been made. The income statement for the year ended 31st December 2003 is unaffected, but
for the quarter ended 31st March 2004 and the six months ended 30th June 2004 profit before tax increased by £4
million and £7 million, respectively, from those presented on 29th October 2004.
The financial information presented within this document is unaudited.
IFRS 1 exemptions
IFRS 1, First-Time Adoption of International Financial Reporting Standards, permits those companies adopting
IFRS for the first time to take some exemptions from the full requirements of IFRS in the transition period.
GlaxoSmithKline intends to take the following key exemptions:
(a) Business combinations: Business combinations prior to the transition date (1st January 2003) have not been
restated onto an IFRS basis;
(b) Employee benefits: All cumulative actuarial gains and losses have been recognised in equity at the
transition date;
(c) Share-based payments: IFRS 2, Share-based Payment, applies to share-based instruments, such as share
options, granted after 7th November 2002, but GlaxoSmithKline has elected to adopt full retrospective
application of the Standard;
(d) Financial instruments: Financial instruments in the comparative periods to be presented in the Annual
Report 2005 (i.e. 2004 and 2003) are recorded on the existing UK GAAP basis, rather than in accordance with
IAS 32, Financial Instruments: Disclosure and Presentation, and IAS 39, Financial Instruments: Recognition
and Measurement (see below).
The financial information contained in this document has been prepared on the basis of taking these exemptions.
Financial instruments
One of the exemptions available under IFRS 1 relaxes the requirement for comparative information to be presented
in the Annual Report 2005 to comply with IAS 32 and IAS 39. GlaxoSmithKline intends to take advantage of this
exemption, and so in 2003 and 2004 financial instruments will continue to be accounted for and presented on a UK
GAAP basis. On 1st January 2005 there is an adjustment to the opening balance sheet to reflect the movements
from the UK GAAP carrying values to the IAS 39 values, which for many financial instruments will be fair value.
The financial instruments concerned are:
(a) Held at fair value under IFRS with movements recorded in equity:
• Equity investments
• Liquid investments
• Derivatives classified as cash flow hedging instruments.
(b) Held at fair value under IFRS with movements recorded in the income statement:
• Equity collar linked to the Group's investment in Quest Diagnostics, Inc.
• Put and call options linked to the Group's strategic alliance with Theravance, Inc.
• Other derivatives not classified as hedging instruments, including embedded derivatives
• Derivatives classified as fair value hedges together with the hedged element of the relevant asset or
liability.
(c) Presentation differences only
• Non-equity minority interests (repaid during 2004).
Although valuations are inherently unpredictable, the only items that are likely to have a material impact are the Quest
collar and the Theravance put and call options. If the IAS 39 valuation rules had been applied in 2004 the overall
effect would have been to reduce profit before tax by some £98 million, principally arising from a reduction in the
value of the Quest collar (£42 million) and the recognition of the net liability for the Theravance put and call options
(£53 million).
Effective tax rate
The effective rate of taxation for 2003 IFRS restated financial statements is 27.7%. This is the rate which was
forecast to apply throughout 2004 and is therefore the rate which was applied to the results for the first three
quarters of 2004. The actual tax rate for the full year 2004 was 30.4%. This increase was partly attributable to an
increase in the UK GAAP tax rate for the year and partly to a non-recurring increase in deferred tax arising from the
different treatments of certain intercompany items between UK GAAP and IFRS.
Presentation of the financial statements
The financial statements contained in this document adopt an IFRS style but with a UK GAAP emphasis in order to minimise
the number of restatement adjustments. It is possible that certain aspects of the presentation of these financial
statements may change as further guidance is issued or a different reporting practice is established.
UK GAAP restatement for 2003
The UK GAAP results for 2003 have been restated following the implementation of UITF Abstract 38, Accounting for ESOP
Trusts, and related amendments to Abstract 17, Employee Share Schemes. UITF 38 changed the presentation of an entity's
own shares held in an ESOP trust from requiring them to be recognised as assets to requiring them to be deducted in
arriving at shareholders' funds. UITF 17 (revised) requires that the minimum expense should be the difference between
the fair value of the shares at the date of award and the amount that an employee may be required to pay for the shares
(i.e. the intrinsic value of the award), spread over the vesting period. The restated information for 2003 has been
presented in the quarterly UK GAAP Results Announcements in 2004.
Further information
This document was approved by the Board of Directors on 10th February 2005 and is available on the company's website:
www.gsk.com or in hard copy from the Company Secretary.
Income statement
Explanation of IFRS income statement adjustments
2003 Full year
2004 Quarter 1
2004 Quarter 2
2004 Half-year
2004 Quarter 3
2004 9 months
2004 Quarter 4
2004 Full year
Explanation of IFRS income statement adjustments
A summary of the principal differences between UK GAAP and IFRS as they apply to GlaxoSmithKline are as follows:
(a) Customer allowances
This adjustment is a reclassification between turnover and expenses with no profit or cash flow effect. IFRS has no
detailed rules in relation to when certain marketing and promotional expenditure should be deducted from turnover
rather than recorded as an expense. However these rules do exist under US GAAP in EITF 01-09, Accounting for
Consideration Given by a Vendor to a Customer, which requires most marketing, advertising, and promotion payments made
to customers to be deducted from turnover. This has the most significant impact in the Consumer Healthcare business
where payments to large retailers for in-store advertising, preferential shelf-space, product listings etc. are
commonplace.
GlaxoSmithKline believes that this reflects best practice in revenue recognition and hence, in the absence of detailed
guidance under IFRS, has decided to adopt a revenue recognition policy under IFRS in line with EITF 01-09. Therefore
going forward there would be no difference between turnover reported under IFRS and turnover reported under US GAAP.
(b) Share-based payments
The present UK GAAP approach to share-based payments is to record any intrinsic loss on grant suffered by the company.
This means that for share options granted at the market price, there is no charge to the income statement. Where shares
or options are granted at no cost to the employee (e.g. under long-term incentive plans) the income statement is
charged with an amount equal to the market price on the date of the award, spread over the performance period (usually
three years).
IFRS 2, Share-based Payment, and its UK GAAP equivalent, FRS 20, both of which come into force in 2005, requires the
fair value of the equity instruments issued to be charged to the income statement. For share awards granted to senior
executives, although the calculation is different, the resultant charge is not materially different from that under UK
GAAP. The major difference arises in respect of share options; of the £368 million adjustment in 2003 some £350
million arises from the grant of share options at market price to approximately 12,000 employees. GlaxoSmithKline has
chosen to recognise all unvested options and awards retrospectively.
The impact of IFRS on share-based payments in 2004 fell to £309 million and is expected to reduce to £200-£250 million
in 2005. The considerably higher charge in 2003 arises from two main factors. Relatively few share options were
granted during 2000 when the GW/SB merger was being finalised, but then in 2001 there was a full "catch-up" grant early
in the year followed by the normal annual grant in November 2001. In addition, the grants in 2001 were made at an
average share price in excess of £18. These share options became exercisable in 2004 and therefore fall out of the
charge in 2005, when the charge will reflect more current share prices and more normal grant levels.
GlaxoSmithKline receives a tax credit, as appropriate, which relates to share options and awards when exercised, based
on the gains the holders make and dependent on the tax rules in the country in which the deduction is claimed. The
deferred tax asset represents an estimate of future tax relief for this gain and is based on the potential gains
available to the option or award holders at the balance sheet date. The movement in deferred tax asset from one
balance sheet to the next may result in either a tax credit or tax charge in the income statement.
(c) Coreg amortisation
The North American rights to Coreg were acquired at the time of the GW/SB merger as partial consideration for the
required disposal of Kytril to Roche. Under UK GAAP this was accounted for as an exchange of assets with no value being
attributed to Coreg on the balance sheet. IFRS, however, requires the acquired rights to Coreg to be added to
intangible assets at their fair value on the date of acquisition of $400 million, and then amortised over their
remaining useful life of eight years.
(d) Other intangible assets amortisation
Under UK GAAP, GlaxoSmithKline amortises intangible assets over their estimated expected useful lives from acquisition,
which can be up to a maximum of 15 years. IFRS only permits amortisation to commence when the asset becomes available
for use, with annual impairment testing required before this point. GlaxoSmithKline has determined that the point at
which amortisation of product-related assets commences under IFRS will normally be regulatory approval. The majority
of GlaxoSmithKline's intangible assets relates to the acquisition of rights to compounds in development and so has not
reached the point at which amortisation commences. This has led to a reduction in the amortisation charge in the
periods presented, but it is likely to increase in the future as these compounds reach regulatory approval and
amortisation is then charged over a shorter period.
(e) Goodwill amortisation
UK GAAP requires goodwill to be amortised over its estimated expected useful life, which GlaxoSmithKline has determined
to be normally no longer than 20 years. Under IFRS, however, goodwill is considered to have an indefinite life and so
is not amortised, but is subject to annual impairment testing. This adjustment therefore reverses the goodwill
amortisation charged under UK GAAP, including that recorded in the profit on share of associates line relating to the
acquisition of the Group's interest in Quest Diagnostics, Inc. Under the business combinations exemption of IFRS 1,
goodwill previously written off direct to reserves under UK GAAP is not recycled to the income statement on the
disposal or part-disposal of the subsidiary or associate, as it would be under UK GAAP. The adjustment relating to the
disposal of part of the Group's interest in Quest Diagnostics, Inc. is also reflected here.
(f) Pensions and other post-employment benefits
GlaxoSmithKline accounts under UK GAAP for pensions and other post-employment benefits (OPEBs) in accordance with SSAP
24, which spreads the costs of providing the benefits over the estimated average service lives of the employees. The
additional FRS 17 disclosures give the pension fund surpluses and deficits and the liabilities for OPEBs based on the
valuation methodologies required by that Standard.
IAS 19 takes a similar valuation approach to FRS 17, and in accordance with the transitional provisions of IFRS 1 the
surpluses and deficits have been recognised on the balance sheet at the transition date of 1st January 2003. In
addition, following an amendment to IAS 19 issued by the IASB in December 2004, it is permitted to recognise any
movements in the surpluses or deficits immediately in balance sheets, but outside the income statement, in a similar
way to FRS 17. This means that, in most cases, the balance sheet reflects the full surplus or deficit positions of the
funds. The income statement for the year ended 31st December 2003 is unaffected, but for the quarter ended 31st March
2004 and the six months ended 30th June 2004 profit before tax increased by £4 million and £7 million, respectively,
from those presented on 29th October 2004.
The Group's policy is to charge out to the operating businesses the service cost element of the pension charge, which
then gets reported within Cost of Sales, S,G&A or R&D as appropriate, but not to charge out the element related to the
funding deficit, which is all reported in S,G&A. Under IAS 19, the service cost element of the total charge is
considerably higher than under SSAP 24 and the funding deficit element lower. This leads to an additional
reclassification adjustment between the income statement expense headings.
In the USA, the recently enacted Medicare Prescription Drug, Improvement and Modernization Act is expected to lead to
payments being received by GlaxoSmithKline from the US Government in respect of its employee healthcare plans. At
present there is no clear guidance on how these receipts should be accounted for under IAS 19. GlaxoSmithKline has
recognised these potential receipts as a reduction in the actuarial loss during 2003. This treatment will change if
guidance is issued which requires a different accounting treatment.
(g) Share of profits of associates
The share of profits of associates is reported within profit before tax for the Group. However, IFRS requires this
share of profits to be the net profit attributable to the Group, i.e. after interest, tax and minority interests of the
associate. This leads to a reclassification adjustment removing the share of the associates' interest, tax and
minority interests from those lines in the income statement and netting them all together in the share of profits of
associates line.
(h) Other adjustments
There are a number of other minor adjustments and reclassifications, the most significant of which relates to deferred
tax on intercompany profit in inventory.
Under UK GAAP, deferred tax on the provision for intercompany profit held in inventory is calculated at the supplying
company's effective tax rate. IFRS, however, takes a balance sheet approach to the recognition of deferred tax which
results in the tax rate of the company holding the inventory at the balance sheet date being applied to the provision.
If the proportions of the Group's inventory held in specific locations change significantly from one balance sheet
date to the next there could be a significant change in the value of the deferred tax asset, which is reflected through
the tax charge for the year.
INCOME STATEMENT
Year ended 31st December 2003
Merger,
UK GAAP restructuring
business IFRS IFRS and disposal
performance adjustments business of businesses IFRS
(Note 1) (Note 2) performance (Note 3) statutory
£m £m £m £m £m
--- --- --- --- ---
TURNOVER
Pharmaceuticals 18,181 (67) 18,114 - 18,114
Consumer Healthcare 3,260 (304) 2,956 - 2,956
--- --- --- --- ---
21,441 (371) 21,070 - 21,070
Cost of sales (4,188) (33) (4,221) (356) (4,577)
--- --- --- --- ---
Gross profit 17,253 (404) 16,849 (356) 16,493
% of sales 80.5% 80.0% 78.3%
Selling, general and administration (7,579) 145 (7,434) (18) (7,452)
% of sales 35.4% 35.3% 35.4%
Research and development (2,770) (74) (2,844) (21) (2,865)
% of sales 12.9% 13.5% 13.6%
--- --- --- --- ---
TRADING PROFIT 6,904 (333) 6,571 (395) 6,176
% of sales 32.2% 31.2% 29.3%
Other operating income/(expense) (133) 7 (126) - (126)
--- --- --- --- ---
Operating profit 6,771 (326) 6,445 (395) 6,050
Share of after tax profits/(losses) of joint 93 (36) 57 - 57
ventures and associates
Profit on disposal of business - - - 5 5
--- --- --- --- ---
Profit before interest 6,864 (362) 6,502 (390) 6,112
Finance costs, net (161) 8 (153) - (153)
--- --- --- --- ---
PROFIT BEFORE TAXATION 6,703 (354) 6,349 (390) 5,959
Taxation (1,838) 78 (1,760) 109 (1,651)
Tax rate % 27.4% 27.7% 27.7%
--- --- --- --- ---
Profit after taxation 4,865 (276) 4,589 (281) 4,308
Equity minority interests (94) (1) (95) - (95)
Preference share dividends (12) - (12) - (12)
--- --- --- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 4,759 (277) 4,482 (281) 4,201
--- --- --- --- ---
EARNINGS PER SHARE 82.0p (4.8)p 77.2p (4.9)p 72.3p
--- --- --- --- ---
Diluted earnings per share 81.7p (4.7)p 77.0p (4.9)p 72.1p
--- --- --- --- ---
Weighted average number of shares (millions) 5,806 5,806 5,806
--- --- ---
Notes:
1. The UK GAAP business performance results have been restated for the implementation of UITF 38 and UITF 17
(revised).
2. The analysis of these adjustments is shown on the next page.
3. There are no IFRS adjustments on merger, restructuring and disposal of businesses.
Analysis of IFRS adjustments to the Income Statement
Year ended 31st December 2003
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (371) - - - - - - - (371)
Cost of sales 20 (41) - - - (12) - - (33)
--- --- --- --- --- --- --- -- ---
Gross profit (351) (41) - - - (12) - - (404)
Selling, general 351 (220) (31) - 13 31 - 1 145
and
administration
Research and - (107) - 42 - (8) - (1) (74)
development
--- --- --- --- --- --- --- --- ---
Trading profit - (368) (31) 42 13 11 - - (333)
Other operating - - - - - - - 7 7
income/(expenses)
--- --- --- --- --- --- --- -- ---
Operating profit - (368) (31) 42 13 11 - 7 (326)
Share of after - - - 1 13 - (50) - (36)
tax profits/
(losses) of joint
ventures and
associates
--- --- --- --- --- --- --- -- ---
Profit before - (368) (31) 43 26 11 (50) 7 (362)
interest
Finance costs, - - - - - - 8 - 8
net
--- --- --- --- --- --- --- -- ---
Profit before - (368) (31) 43 26 11 (42) 7 (354)
taxation
Taxation - 24 10 (13) - (7) 40 24 78
--- --- --- --- --- --- --- -- ---
Profit after - (344) (21) 30 26 4 (2) 31 (276)
taxation
Minority - - - - - (3) 2 - (1)
interests
--- --- --- --- --- --- --- -- ---
Profit - (344) (21) 30 26 1 - 31 (277)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (5.9)p (0.3)p 0.5p 0.4p - - 0.5p (4.8)p
share (basic)
--- --- --- --- --- --- --- -- ---
INCOME STATEMENT
Three months ended 31st March 2004
IFRS
adjustments
UK GAAP (Note) IFRS
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 4,180 (12) 4,168
Consumer Healthcare 763 (76) 687
--- --- ---
4,943 (88) 4,855
Cost of sales (1,024) (11) (1,035)
--- --- ---
Gross profit 3,919 (99) 3,820
% of sales 79.3% 78.7%
Selling, general and administration (1,726) 23 (1,703)
% of sales 34.9% 35.1%
Research and development (631) (28) (659)
% of sales 12.8% 13.6%
--- --- ---
TRADING PROFIT 1,562 (104) 1,458
% of sales 31.6% 30.0%
Other operating income/(expense) 35 - 35
--- --- ---
Operating profit 1,597 (104) 1,493
Share of after tax profits/(losses) of joint ventures and associates 22 (8) 14
--- --- ---
Profit before interest 1,619 (112) 1,507
Finance costs, net (43) 2 (41)
--- --- ---
PROFIT BEFORE TAXATION 1,576 (110) 1,466
Taxation (433) 27 (406)
Tax rate % 27.5% 27.7%
--- --- ---
Profit after taxation 1,143 (83) 1,060
Equity minority interests (22) 1 (21)
Preference share dividends (2) - (2)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 1,119 (82) 1,037
--- --- ---
EARNINGS PER SHARE 19.4p (1.4)p 18.0p
--- --- ---
Diluted earnings per share 19.4p (1.4)p 18.0p
--- --- ---
Weighted average number of shares 5,768 5,768
(millions)
--- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Three months ended 31st March 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (88) - - - - - - - (88)
Cost of sales 6 (12) - - - (6) - 1 (11)
--- --- --- --- --- --- --- -- ---
Gross profit (82) (12) - - - (6) - 1 (99)
Selling, general 82 (62) (6) - 3 7 - (1) 23
and
administration
Research and - (30) - 9 - (6) - (1) (28)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (104) (6) 9 3 (5) - (1) (104)
--- --- --- --- --- --- --- -- ---
Operating profit - (104) (6) 9 3 (5) - (1) (104)
Share of after - - - - 3 - (11) - (8)
tax profits/
(losses) of joint
ventures and
associates
--- --- --- --- --- --- --- -- ---
Profit before - (104) (6) 9 6 (5) (11) (1) (112)
interest
Finance costs, - - - - - - 2 - 2
net
--- --- --- --- --- --- --- -- ---
Profit before - (104) (6) 9 6 (5) (9) (1) (110)
taxation
Taxation - 7 2 (3) - 2 8 11 27
--- --- --- --- --- --- --- -- ---
Profit after - (97) (4) 6 6 (3) (1) 10 (83)
taxation
Minority - - - - - - 1 - 1
interests
--- --- --- --- --- --- --- -- ---
Profit - (97) (4) 6 6 (3) - 10 (82)
attributable to
shareholders
--- --- --- --- --- --- --- --- ---
Earnings per - (1.7)p (0.1)p 0.1p 0.1p - - 0.2p (1.4)p
share (basic)
--- --- --- --- --- --- --- --- ---
INCOME STATEMENT
Three months ended 30th June 2004
IFRS
adjustments IFRS
UK GAAP (Note) statutory
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 4,266 (11) 4,255
Consumer Healthcare 798 (82) 716
--- --- ---
5,064 (93) 4,971
Cost of sales (1,031) (13) (1,044)
--- --- ---
Gross profit 4,033 (106) 3,927
% of sales 79.6% 79.0%
Selling, general and administration (1,641) 37 (1,604)
% of sales 32.4% 32.3%
Research and development (680) (16) (696)
% of sales 13.4% 14.0%
--- --- ---
TRADING PROFIT 1,712 (85) 1,627
% of sales 33.8% 32.7%
Other operating income/(expense) (102) - (102)
--- --- ---
Operating profit 1,610 (85) 1,525
Share of after tax profits/(losses) of joint ventures and associates 28 (12) 16
Profit on disposal of interest in associate 41 4 45
--- --- ---
Profit before interest 1,679 (93) 1,586
Finance costs, net (48) 2 (46)
--- --- ---
PROFIT BEFORE TAXATION 1,631 (91) 1,540
Taxation (449) 23 (426)
Tax rate % 27.5% 27.7%
--- --- ---
Profit after taxation 1,182 (68) 1,114
Equity minority interests (25) - (25)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 1,157 (68) 1,089
--- --- ---
EARNINGS PER SHARE 20.1p (1.2)p 18.9p
--- --- ---
Diluted earnings per share 20.1p (1.2)p 18.9p
--- --- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Three months ended 30th June 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (93) - - - - - - - (93)
Cost of sales - (8) - - - (4) - (1) (13)
--- --- --- --- --- --- --- -- ---
Gross profit (93) (8) - - - (4) - (1) (106)
Selling, general 93 (47) (7) - 3 (5) - - 37
and
administration
Research and - (22) - 11 - (4) - (1) (16)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (77) (7) 11 3 (13) - (2) (85)
--- --- --- --- --- --- --- -- ---
Operating profit - (77) (7) 11 3 (13) - (2) (85)
Share of after - - - - 2 - (14) - (12)
tax profits/
(losses) of joint
ventures and
associates
Profit on - - - - 4 - - - 4
disposal of
interest in
associates
--- --- --- --- --- --- --- -- ---
Profit before - (77) (7) 11 9 (13) (14) (2) (93)
interest
Finance costs, - - - - - - 2 - 2
net
--- --- --- --- --- --- --- -- ---
Profit before - (77) (7) 11 9 (13) (12) (2) (91)
taxation
Taxation - 5 2 (4) - 5 12 3 23
--- --- --- --- --- --- --- -- ---
Profit after - (72) (5) 7 9 (8) - 1 (68)
taxation
--- --- --- --- --- --- --- -- ---
Profit - (72) (5) 7 9 (8) - 1 (68)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (1.2)p (0.1)p 0.1p 0.2p (0.2)p - - (1.2)p
share (basic)
--- --- --- --- --- --- --- -- ---
INCOME STATEMENT
Six months ended 30th June 2004
IFRS
adjustments IFRS
UK GAAP (Note) statutory
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 8,446 (23) 8,423
Consumer Healthcare 1,561 (158) 1,403
--- --- ---
10,007 (181) 9,826
Cost of sales (2,055) (24) (2,079)
--- --- ---
Gross profit 7,952 (205) 7,747
% of sales 79.5% 78.8%
Selling, general and administration (3,367) 60 (3,307)
% of sales 33.7% 33.6%
Research and development (1,311) (44) (1,355)
% of sales 13.1% 13.8%
--- --- ---
TRADING PROFIT 3,274 (189) 3,085
% of sales 32.7% 31.4%
Other operating income/(expense) (67) - (67)
--- --- ---
Operating profit 3,207 (189) 3,018
Share of after tax profits/(losses) of joint ventures and associates 50 (20) 30
Profit on disposal of interest in associate 41 4 45
--- --- ---
Profit before interest 3,298 (205) 3,093
Finance costs, net (91) 4 (87)
--- --- ---
PROFIT BEFORE TAXATION 3,207 (201) 3,006
Taxation (882) 50 (832)
Tax rate % 27.5% 27.7%
--- --- ---
Profit after taxation 2,325 (151) 2,174
Equity minority interests (47) 1 (46)
Preference share dividends (2) - (2)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 2,276 (150) 2,126
--- --- ---
EARNINGS PER SHARE 39.5p (2.6)p 36.9p
--- --- ---
Diluted earnings per share 39.5p (2.6)p 36.9p
--- --- ---
Weighted average number of shares 5,756 5,756
(millions)
--- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Six months ended 30th June 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (181) - - - - - - - (181)
Cost of sales 6 (20) - - - (10) - - (24)
--- --- --- --- --- --- --- -- ---
Gross profit (175) (20) - - - (10) - - (205)
Selling, general 175 (109) (13) - 6 2 - (1) 60
and
administration
Research and - (52) - 20 - (10) - (2) (44)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (181) (13) 20 6 (18) - (3) (189)
--- --- --- --- --- --- --- -- ---
Operating profit - (181) (13) 20 6 (18) - (3) (189)
Share of after - - - - 5 - (25) - (20)
tax profits/
(losses) of joint
ventures and
associates
Profit on - - - - 4 - - - 4
disposal of
interest in
associate
--- --- --- --- --- --- --- -- ---
Profit before - (181) (13) 20 15 (18) (25) (3) (205)
interest
Finance costs, - - - - - - 4 - 4
net
--- --- --- --- --- --- --- -- ---
Profit before - (181) (13) 20 15 (18) (21) (3) (201)
taxation
Taxation - 12 4 (7) - 7 20 14 50
--- --- --- --- --- --- --- -- ---
Profit after - (169) (9) 13 15 (11) (1) 11 (151)
taxation
Minority - - - - - - 1 - 1
interests
--- --- --- --- --- --- --- -- ---
Profit - (169) (9) 13 15 (11) - 11 (150)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (2.9)p (0.2)p 0.2p 0.3p (0.2)p - 0.2p (2.6)p
share (basic)
--- --- --- --- --- --- --- -- ---
INCOME STATEMENT
Three months ended 30th September 2004
IFRS
adjustments
UK GAAP (Note) IFRS
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 4,213 (11) 4,202
Consumer Healthcare 806 (84) 722
--- --- ---
5,019 (95) 4,924
Cost of sales (1,096) (9) (1,105)
--- --- ---
Gross profit 3,923 (104) 3,819
% of sales 78.2% 77.6%
Selling, general and administration (1,647) 54 (1,593)
% of sales 32.8% 32.4%
Research and development (682) (14) (696)
% of sales 13.6% 14.1%
--- --- ---
TRADING PROFIT 1,594 (64) 1,530
% of sales 31.8% 31.1%
Other operating income/(expense) (33) - (33)
--- --- ---
Operating profit 1,561 (64) 1,497
Share of after tax profits/(losses) of joint ventures and associates 22 (8) 14
--- --- ---
Profit before interest 1,583 (72) 1,511
Finance costs, net (61) 1 (60)
--- --- ---
PROFIT BEFORE TAXATION 1,522 (71) 1,451
Taxation (418) 14 (404)
Tax rate % 27.5% 27.8%
--- --- ---
Profit after taxation 1,104 (57) 1,047
Equity minority interests (39) - (39)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 1,065 (57) 1,008
--- --- ---
EARNINGS PER SHARE 18.7p (1.0)p 17.7p
--- --- ---
Diluted earnings per share 18.5p (0.9)p 17.6p
--- --- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Three months ended 30th September 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (95) - - - - - - - (95)
Cost of sales 7 (9) - - - (6) - (1) (9)
--- --- --- --- --- --- --- -- ---
Gross profit (88) (9) - - - (6) - (1) (104)
Selling, general 88 (40) (8) - 3 9 - 2 54
and
administration
Research and - (22) - 11 - (5) - 2 (14)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (71) (8) 11 3 (2) - 3 (64)
--- --- --- --- --- --- --- -- ---
Operating profit - (71) (8) 11 3 (2) - 3 (64)
Share of after - - - - 4 - (12) - (8)
tax profits/
(losses) of joint
ventures and
associates
--- --- --- --- --- --- --- -- ---
Profit before - (71) (8) 11 7 (2) (12) 3 (72)
interest
Finance costs, - - - - - - 1 - 1
net
--- --- --- --- --- --- --- -- ---
Profit before - (71) (8) 11 7 (2) (11) 3 (71)
taxation
Taxation - 4 3 (4) - - 10 1 14
--- --- --- --- --- --- --- -- ---
Profit after - (67) (5) 7 7 (2) (1) 4 (57)
taxation
Minority - - - - - (1) 1 - -
interests
--- --- --- --- --- --- --- -- ---
Profit - (67) (5) 7 7 (3) - 4 (57)
attributable to
shareholders
--- --- --- --- --- --- --- --- ---
Earnings per - (1.2)p - 0.1p 0.1p - - - (1.0)p
share (basic)
--- --- --- --- --- --- --- --- ---
INCOME STATEMENT
Nine months ended 30th September 2004
IFRS
adjustments IFRS
UK GAAP (Note) statutory
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 12,659 (34) 12,625
Consumer Healthcare 2,367 (242) 2,125
--- --- ---
15,026 (276) 14,750
Cost of sales (3,151) (33) (3,184)
--- --- ---
Gross profit 11,875 (309) 11,566
% of sales 79.0% 78.4%
Selling, general and administration (5,014) 114 (4,900)
% of sales 33.3% 33.2%
Research and development (1,993) (58) (2,051)
% of sales 13.3% 13.9%
--- --- ---
TRADING PROFIT 4,868 (253) 4,615
% of sales 32.4% 31.3%
Other operating income/(expense) (100) - (100)
--- --- ---
Operating profit 4,768 (253) 4,515
Share of after tax profits/(losses) of joint ventures and associates 72 (28) 44
Profit on disposal of interest in associate 41 4 45
--- --- ---
Profit before interest 4,881 (277) 4,604
Finance costs, net (152) 5 (147)
--- --- ---
PROFIT BEFORE TAXATION 4,729 (272) 4,457
Taxation (1,300) 64 (1,236)
Tax rate % 27.5% 27.7%
--- --- ---
Profit after taxation 3,429 (208) 3,221
Equity minority interests (86) 1 (85)
Preference share dividends (2) - (2)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 3,341 (207) 3,134
--- --- ---
EARNINGS PER SHARE 58.2p (3.6)p 54.6p
--- --- ---
Diluted earnings per share 58.0p (3.5)p 54.5p
--- --- ---
Weighted average number of shares 5,745 5,745
(millions)
--- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Nine months ended 30th September 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (276) - - - - - - - (276)
Cost of sales 13 (29) - - - (16) - (1) (33)
--- --- --- --- --- --- --- -- ---
Gross profit (263) (29) - - - (16) - (1) (309)
Selling, general 263 (149) (21) - 9 11 - 1 114
and
administration
Research and - (74) - 31 - (15) - - (58)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (252) (21) 31 9 (20) - - (253)
--- --- --- --- --- --- --- -- ---
Operating profit - (252) (21) 31 9 (20) - - (253)
Share of after - - - - 9 - (37) - (28)
tax profits/
(losses) of joint
ventures and
associates
Profit on - - - - 4 - - - 4
disposal of
interest in
associate
--- --- --- --- --- --- --- -- ---
Profit before - (252) (21) 31 22 (20) (37) - (277)
interest
Finance costs, - - - - - - 5 - 5
net
--- --- --- --- --- --- --- -- ---
Profit before - (252) (21) 31 22 (20) (32) - (272)
taxation
Taxation - 16 7 (11) - 7 30 15 64
--- --- --- --- --- --- --- -- ---
Profit after - (236) (14) 20 22 (13) (2) 15 (208)
taxation
Minority - - - - - (1) 2 - 1
interests
--- --- --- --- --- --- --- -- ---
Profit - (236) (14) 20 22 (14) - 15 (207)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (4.1)p (0.2)p 0.3p 0.4p (0.2)p - 0.2p (3.6)p
share (basic)
--- --- --- --- --- --- --- -- ---
INCOME STATEMENT
Three months ended 31st December 2004
IFRS
adjustments IFRS
UK GAAP (Note) statutory
£m £m £m
--- --- ---
TURNOVER
Pharmaceuticals 4,487 (12) 4,475
Consumer Healthcare 846 (85) 761
--- --- ---
5,333 (97) 5,236
Cost of sales (1,158) (18) (1,176)
--- --- ---
Gross profit 4,175 (115) 4,060
% of sales 78.3% 77.5%
Selling, general and administration (2,047) 42 (2,005)
% of sales 38.4% 38.2%
Research and development (846) (7) (853)
% of sales 15.9% 16.3%
--- --- ---
TRADING PROFIT 1,282 (80) 1,202
% of sales 24.0% 23.0%
Other operating income/(expense) 40 (1) 39
--- --- ---
Operating profit 1,322 (81) 1,241
Share of after tax profits/(losses) of joint ventures and associates 23 (7) 16
Profit on disposal of interest in associate 97 7 104
Business disposals (1) 1 -
--- --- ---
Profit before interest 1,441 (80) 1,361
Finance costs, net (51) 12 (39)
--- --- ---
PROFIT BEFORE TAXATION 1,390 (68) 1,322
Taxation (401) (120) (521)
Tax rate % 28.8% 39.4%
--- --- ---
Profit after taxation 989 (188) 801
Equity minority interests (28) 1 (27)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 961 (187) 774
--- --- ---
EARNINGS PER SHARE 16.8p (3.3)p 13.5p
--- --- ---
Diluted earnings per share 16.8p (3.2)p 13.6p
--- --- ---
Note: The analysis of these adjustments is shown on the next page.
Analysis of IFRS adjustments to the Income Statement
Three months ended 31st December 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (97) - - - - - - - (97)
Cost of sales 1 (7) - - - - - (12) (18)
--- --- --- --- --- --- --- -- ---
Gross profit (96) (7) - - - - - (12) (115)
Selling, general 96 (33) (6) - 3 (14) - (4) 42
and
administration
Research and - (17) - 12 - (2) - - (7)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (57) (6) 12 3 (16) - (16) (80)
Other operating - - - - - - - (1) (1)
income/(expense)
--- --- --- --- --- --- --- -- ---
Operating profit - (57) (6) 12 3 (16) - (17) (81)
Share of after - - - - 5 - (12) - (7)
tax profits/
(losses) of joint
ventures and
associates
Profit on - - - - 7 - - - 7
disposal of
interest in
associates
Business - - - - 1 - - - 1
disposals
--- --- --- --- --- --- --- -- ---
Profit before - (57) (6) 12 16 (16) (12) (17) (80)
interest
Finance costs, - - - - - - 2 10 12
net
--- --- --- --- --- --- --- -- ---
Profit before - (57) (6) 12 16 (16) (10) (7) (68)
taxation
Taxation - (21) 2 (1) - 6 10 (116) (120)
--- --- --- --- --- --- --- -- ---
Profit after - (78) (4) 11 16 (10) - (123) (188)
taxation
Minority - - - - - 1 - - 1
interests
--- --- --- --- --- --- --- -- ---
Profit - (78) (4) 11 16 (9) - (123) (187)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (1.4)p (0.1)p 0.2p 0.3p (0.2)p - (2.1)p (3.3)p
share (basic)
--- --- --- --- --- --- --- -- ---
INCOME STATEMENT
Year ended 31st December 2004
IFRS
adjustments IFRS AR CER
UK GAAP (Note 1) statutory (Note 2) (Note 2)
£m £m £m % %
--- --- --- -- --
TURNOVER
Pharmaceuticals 17,146 (46) 17,100 (6) 1
Consumer Healthcare 3,213 (327) 2,886 (2) 3
--- --- ---
20,359 (373) 19,986 (5) 1
Cost of sales (4,309) (51) (4,360) (3) (9)
--- --- ---
Gross profit 16,050 (424) 15,626 (7) -
% of sales 78.8% 78.2%
Selling, general and administration (7,061) 156 (6,905) (7) (3)
% of sales 34.7% 34.6%
Research and development (2,839) (65) (2,904) 2 9
% of sales 13.9% 14.5%
--- --- ---
TRADING PROFIT 6,150 (333) 5,817 (11) (1)
% of sales 30.2% 29.1%
Other operating income/(expense) (60) (1) (61)
--- --- ---
Operating profit 6,090 (334) 5,756 (11) -
Share of after tax profits/(losses) of joint 95 (35) 60
ventures and associates
Profit on disposal of interest in associates 138 11 149
Business disposals (1) 1 -
--- --- ---
Profit before interest 6,322 (357) 5,965
Finance costs, net (203) 17 (186)
--- --- ---
PROFIT BEFORE TAXATION 6,119 (340) 5,779 (9) 2
Taxation (1,701) (56) (1,757)
Tax rate % 27.8% 30.4%
--- --- ---
Profit after taxation 4,418 (396) 4,022 (12) (2)
Equity minority interests (114) 2 (112)
Preference share dividends (2) - (2)
--- --- ---
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 4,302 (394) 3,908 (13) (2)
--- --- ---
EARNINGS PER SHARE 75.0p (6.9)p 68.1p (12) (1)
--- --- ---
Diluted earnings per share 74.8p (6.8)p 68.0p
--- --- ---
Weighted average number of shares (millions) 5,736 5,736
--- ---
Notes:
1. The analysis of these adjustments is shown on the next page.
2. Growth rates compare 2004 IFRS results with 2003 IFRS business performance results.
Analysis of IFRS adjustments to the Income Statement
Year ended 31st December 2004
Other
Share- Coreg intangible Pensions Share of
Customer based amorti- assets Goodwill and profits of IFRS
allowances payments amortisation amortisation OPEBs associates Other adjust-
(a) (b) sation (d) (e) (f) (g) (h)
(c) ments
£m £m £m £m £m £m £m £m £m
--- --- --- --- --- --- --- -- ---
Turnover (373) - - - - - - - (373)
Cost of sales 14 (36) - - - (16) - (13) (51)
--- --- --- --- --- --- --- -- ---
Gross profit (359) (36) - - - (16) - (13) (424)
Selling, general 359 (182) (27) - 12 (3) - (3) 156
and
administration
Research and - (91) - 43 - (17) - - (65)
development
--- --- --- --- --- --- --- -- ---
Trading profit - (309) (27) 43 12 (36) - (16) (333)
Other operating - - - - - - - (1) (1)
income/(expense)
--- --- --- --- --- --- --- -- ---
Operating profit - (309) (27) 43 12 (36) - (17) (334)
Share of after - - - - 14 - (49) - (35)
tax profits/
(losses) of joint
ventures and
associates
Profit on - - - - 11 - - - 11
disposal of
interest in
associates
Business - - - - 1 - - - 1
disposals
--- --- --- --- --- --- --- -- ---
Profit before - (309) (27) 43 38 (36) (49) (17) (357)
interest
Finance costs, - - - - - - 7 10 17
net
--- --- --- --- --- --- --- -- ---
Profit before - (309) (27) 43 38 (36) (42) (7) (340)
taxation
Taxation - (5) 9 (12) - 13 40 (101)* (56)
--- --- --- --- --- --- --- -- ---
Profit after - (314) (18) 31 38 (23) (2) (108) (396)
taxation
Minority - - - - - - 2 - 2
interests
--- --- --- --- --- --- --- -- ---
Profit - (314) (18) 31 38 (23) - (108) (394)
attributable to
shareholders
--- --- --- --- --- --- --- -- ---
Earnings per - (5.5)p (0.3)p 0.5p 0.7p (0.4)p - (1.9)p (6.9)p
share (basic)
--- --- --- --- --- --- --- -- ---
* This includes a deferred tax charge of £110 million, principally related to intercompany items on which a deferred
tax credit is available under UK GAAP, but not under IFRS. This particular difference in taxation treatment is not
expected to recur.
Turnover
Pharmaceuticals
2003 Full year
2004 Quarter 1
2004 Quarter 2
2004 Half-year
2004 Quarter 3
2004 9 months
2004 Quarter 4
2004 Full year
Consumer Healthcare
2003 Full year
2004 Quarter 1
2004 Quarter 2
2004 Half-year
2004 Quarter 3
2004 9 months
2004 Quarter 4
2004 Full year
PHARMACEUTICAL TURNOVER
Year ended 31st December 2003
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 4,417 4,390 2,242 2,242 1,481 1,454 694 694
Seretide/Advair, 3,352 3,328 1,750 1,750 1,170 1,146 432 432
Flixotide/Flovent, Serevent
Seretide/Advair 2,214 2,192 1,235 1,235 773 751 206 206
Flixotide/Flovent 705 704 319 319 208 207 178 178
Serevent 433 432 196 196 189 188 48 48
Flixonase/Flonase 594 594 461 461 56 56 77 77
CENTRAL NERVOUS SYSTEM 4,455 4,446 3,112 3,112 847 838 496 496
Depression 2,830 2,830 2,107 2,107 369 369 354 354
Seroxat/Paxil 1,877 1,877 1,179 1,179 369 369 329 329
Wellbutrin 953 953 928 928 - - 25 25
Migraine 849 848 609 609 179 178 61 61
Imigran/Imitrex 760 759 560 560 147 146 53 53
Lamictal 556 549 311 311 202 195 43 43
Requip 99 98 47 47 47 46 5 5
ANTI-VIRALS 2,349 2,345 1,159 1,159 726 722 464 464
HIV 1,508 1,505 798 798 555 552 155 155
Combivir 589 588 301 301 218 217 70 70
Trizivir 376 375 219 219 143 142 14 14
Epivir 293 293 148 148 107 107 38 38
Ziagen 167 167 86 86 61 61 20 20
Agenerase, Lexiva 31 31 19 19 9 9 3 3
Herpes 669 668 325 325 148 147 196 196
Valtrex 499 498 316 316 86 85 97 97
Zovirax 170 170 9 9 62 62 99 99
Zeffix 129 129 10 10 17 17 102 102
ANTI-BACTERIALS 1,815 1,800 524 524 755 741 536 535
Augmentin 825 825 312 312 332 332 181 181
Zinnat/Ceftin 246 232 22 22 134 121 90 89
METABOLIC 1,079 1,077 755 755 116 114 208 208
Avandia, Avandamet 931 929 755 755 70 68 106 106
VACCINES 1,123 1,121 281 281 495 493 347 347
Hepatitis 417 417 157 157 192 192 68 68
Infanrix, Pediarix 336 336 124 124 147 147 65 65
ONCOLOGY AND EMESIS 1,001 1,000 743 743 163 163 95 94
Zofran 774 774 575 575 126 126 73 73
Hycamtin 110 110 77 77 25 25 8 8
CARDIOVASCULAR AND UROGENITAL 771 770 495 495 176 175 100 100
Coreg 361 361 346 346 - - 15 15
Levitra 37 37 22 22 11 11 4 4
Avodart 19 19 14 14 5 5 - -
OTHER 1,171 1,165 99 99 355 350 717 716
Zantac 328 328 77 77 94 94 157 157
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 18,181 18,114 9,410 9,410 5,114 5,050 3,657 3,654
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Three months ended 31st March 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 1,086 1,082 548 548 374 370 164 164
Seretide/Advair, 824 820 416 416 301 297 107 107
Flixotide/Flovent, Serevent
Seretide/Advair 581 577 317 317 211 207 53 53
Flixotide/Flovent 154 154 63 63 48 48 43 43
Serevent 89 89 36 36 42 42 11 11
Flixonase/Flonase 157 157 126 126 14 14 17 17
CENTRAL NERVOUS SYSTEM 914 914 612 612 193 193 109 109
Depression 512 512 365 365 71 71 76 76
Seroxat/Paxil 291 291 148 148 71 71 72 72
Wellbutrin 221 221 217 217 - - 4 4
Migraine 192 192 135 135 44 44 13 13
Imigran/Imitrex 172 172 126 126 35 35 11 11
Lamictal 153 153 91 91 51 51 11 11
Requip 26 26 12 12 13 13 1 1
ANTI-VIRALS 562 562 271 271 183 183 108 108
HIV 348 348 172 172 140 140 36 36
Combivir 139 139 68 68 56 56 15 15
Trizivir 81 81 43 43 34 34 4 4
Epivir 71 71 33 33 29 29 9 9
Ziagen 38 38 18 18 15 15 5 5
Agenerase, Lexiva 9 9 6 6 2 2 1 1
Herpes 174 174 89 89 37 37 48 48
Valtrex 133 133 86 86 22 22 25 25
Zovirax 41 41 3 3 15 15 23 23
Zeffix 30 30 3 3 5 5 22 22
ANTI-BACTERIALS 426 422 111 111 194 190 121 121
Augmentin 204 204 78 78 82 82 44 44
Zinnat/Ceftin 63 59 4 4 41 37 18 18
METABOLIC 270 269 185 185 31 30 54 54
Avandia, Avandamet 238 237 185 185 22 21 31 31
VACCINES 240 239 55 55 101 100 84 84
Hepatitis 90 90 31 31 42 42 17 17
Infanrix, Pediarix 76 76 24 24 35 35 17 17
ONCOLOGY AND EMESIS 222 222 160 160 42 42 20 20
Zofran 180 180 132 132 32 32 16 16
Hycamtin 24 24 16 16 7 7 1 1
CARDIOVASCULAR AND UROGENITAL 200 200 129 129 49 49 22 22
Coreg 94 94 91 91 - - 3 3
Levitra 17 17 11 11 5 5 1 1
Avodart 10 10 6 6 4 4 - -
OTHER 260 258 22 22 79 77 159 159
Zantac 68 68 17 17 20 20 31 31
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 4,180 4,168 2,093 2,093 1,246 1,234 841 841
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Three months ended 30th June 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 1,086 1,080 511 511 403 397 172 172
Seretide/Advair, 852 847 405 405 329 324 118 118
Flixotide/Flovent, Serevent
Seretide/Advair 603 598 304 304 240 235 59 59
Flixotide/Flovent 156 156 65 65 48 48 43 43
Serevent 93 93 36 36 41 41 16 16
Flixonase/Flonase 133 133 100 100 19 19 14 14
CENTRAL NERVOUS SYSTEM 877 877 579 579 191 191 107 107
Depression 477 477 337 337 67 67 73 73
Seroxat/Paxil 284 284 146 146 67 67 71 71
Wellbutrin 193 193 191 191 - - 2 2
Migraine 176 176 117 117 44 44 15 15
Imigran/Imitrex 158 158 109 109 36 36 13 13
Lamictal 171 171 104 104 56 56 11 11
Requip 29 29 13 13 14 14 2 2
ANTI-VIRALS 595 595 296 296 183 183 116 116
HIV 368 368 191 191 141 141 36 36
Combivir 141 141 69 69 56 56 16 16
Trizivir 87 87 49 49 34 34 4 4
Epivir 77 77 39 39 29 29 9 9
Ziagen 37 37 18 18 15 15 4 4
Agenerase, Lexiva 15 15 12 12 3 3 - -
Herpes 182 182 97 97 35 35 50 50
Valtrex 145 145 95 95 23 23 27 27
Zovirax 37 37 2 2 12 12 23 23
Zeffix 33 33 2 2 5 5 26 26
ANTI-BACTERIALS 386 382 89 89 169 165 128 128
Augmentin 178 178 53 53 75 75 50 50
Zinnat/Ceftin 52 48 2 2 31 27 19 19
METABOLIC 339 338 233 233 31 30 75 75
Avandia, Avandamet 307 306 233 233 25 24 49 49
VACCINES 278 278 67 67 116 116 95 95
Hepatitis 105 105 35 35 51 51 19 19
Infanrix, Pediarix 86 86 32 32 38 38 16 16
ONCOLOGY AND EMESIS 237 237 172 172 44 44 21 21
Zofran 192 192 141 141 34 34 17 17
Hycamtin 25 25 16 16 7 7 2 2
CARDIOVASCULAR AND UROGENITAL 220 220 141 141 53 53 26 26
Coreg 113 113 112 112 - - 1 1
Levitra 9 9 1 1 5 5 3 3
Avodart 14 14 7 7 6 6 1 1
OTHER 248 248 24 24 73 73 151 151
Zantac 70 70 20 20 18 18 32 32
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 4,266 4,255 2,112 2,112 1,263 1,252 891 891
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Six months ended 30th June 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 2,172 2,162 1,059 1,059 777 767 336 336
Seretide/Advair, 1,676 1,667 821 821 630 621 225 225
Flixotide/Flovent, Serevent
Seretide/Advair 1,184 1,175 621 621 451 442 112 112
Flixotide/Flovent 310 310 128 128 96 96 86 86
Serevent 182 182 72 72 83 83 27 27
Flixonase/Flonase 290 290 226 226 33 33 31 31
CENTRAL NERVOUS SYSTEM 1,791 1,791 1,191 1,191 384 384 216 216
Depression 989 989 702 702 138 138 149 149
Seroxat/Paxil 575 575 294 294 138 138 143 143
Wellbutrin 414 414 408 408 - - 6 6
Migraine 368 368 252 252 88 88 28 28
Imigran/Imitrex 330 330 235 235 71 71 24 24
Lamictal 324 324 195 195 107 107 22 22
Requip 55 55 25 25 27 27 3 3
ANTI-VIRALS 1,157 1,157 567 567 366 366 224 224
HIV 716 716 363 363 281 281 72 72
Combivir 280 280 137 137 112 112 31 31
Trizivir 168 168 92 92 68 68 8 8
Epivir 148 148 72 72 58 58 18 18
Ziagen 75 75 36 36 30 30 9 9
Agenerase, Lexiva 24 24 18 18 5 5 1 1
Herpes 356 356 186 186 72 72 98 98
Valtrex 278 278 181 181 45 45 52 52
Zovirax 78 78 5 5 27 27 46 46
Zeffix 63 63 5 5 10 10 48 48
ANTI-BACTERIALS 812 804 200 200 363 355 249 249
Augmentin 382 382 131 131 157 157 94 94
Zinnat/Ceftin 115 107 6 6 72 64 37 37
METABOLIC 609 607 418 418 62 60 129 129
Avandia, Avandamet 545 543 418 418 47 45 80 80
VACCINES 518 517 122 122 217 216 179 179
Hepatitis 195 195 66 66 93 93 36 36
Infanrix, Pediarix 162 162 56 56 73 73 33 33
ONCOLOGY AND EMESIS 459 459 332 332 86 86 41 41
Zofran 372 372 273 273 66 66 33 33
Hycamtin 49 49 32 32 14 14 3 3
CARDIOVASCULAR AND UROGENITAL 420 420 270 270 102 102 48 48
Coreg 207 207 203 203 - - 4 4
Levitra 26 26 12 12 10 10 4 4
Avodart 24 24 13 13 10 10 1 1
OTHER 508 506 46 46 152 150 310 310
Zantac 138 138 37 37 38 38 63 63
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 8,446 8,423 4,205 4,205 2,509 2,486 1,732 1,732
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Three months ended 30th September 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 1,070 1,065 556 556 358 353 156 156
Seretide/Advair, 832 827 431 431 295 290 106 106
Flixotide/Flovent, Serevent
Seretide/Advair 609 604 342 342 213 208 54 54
Flixotide/Flovent 141 141 59 59 43 43 39 39
Serevent 82 82 30 30 39 39 13 13
Flixonase/Flonase 145 145 119 119 12 12 14 14
CENTRAL NERVOUS SYSTEM 835 835 544 544 181 181 110 110
Depression 419 419 285 285 58 58 76 76
Seroxat/Paxil 246 246 117 117 58 58 71 71
Wellbutrin 173 173 168 168 - - 5 5
Migraine 194 194 136 136 44 44 14 14
Imigran/Imitrex 175 175 127 127 36 36 12 12
Lamictal 172 172 106 106 54 54 12 12
Requip 29 29 13 13 14 14 2 2
ANTI-VIRALS 597 597 307 307 170 170 120 120
HIV 372 372 198 198 132 132 42 42
Combivir 144 144 73 73 54 54 17 17
Trizivir 79 79 47 47 30 30 2 2
Epivir 73 73 35 35 27 27 11 11
Ziagen 42 42 20 20 14 14 8 8
Agenerase, Lexiva 18 18 13 13 3 3 2 2
Herpes 179 179 99 99 31 31 49 49
Valtrex 147 147 96 96 22 22 29 29
Zovirax 32 32 3 3 9 9 20 20
Zeffix 33 33 3 3 6 6 24 24
ANTI-BACTERIALS 353 350 71 71 154 151 128 128
Augmentin 156 156 42 42 63 63 51 51
Zinnat/Ceftin 45 42 1 1 25 22 19 19
METABOLIC 320 320 216 216 36 36 68 68
Avandia, Avandamet 284 284 216 216 27 27 41 41
VACCINES 328 328 67 67 150 150 111 111
Hepatitis 102 101 34 34 52 51 16 16
Infanrix, Pediarix 95 95 33 33 41 41 21 21
ONCOLOGY AND EMESIS 246 246 182 182 42 42 22 22
Zofran 201 201 152 152 32 32 17 17
Hycamtin 26 26 17 17 7 7 2 2
CARDIOVASCULAR AND UROGENITAL 233 232 142 142 64 63 27 27
Coreg 110 110 108 108 - - 2 2
Levitra 11 11 3 3 5 5 3 3
Avodart 17 17 10 10 7 7 - -
OTHER 231 229 21 21 67 66 143 142
Zantac 66 66 17 17 17 17 32 32
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 4,213 4,202 2,106 2,106 1,222 1,212 885 884
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Nine months ended 30th September 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 3,242 3,227 1,615 1,615 1,135 1,120 492 492
Seretide/Advair, 2,508 2,494 1,252 1,252 925 911 331 331
Flixotide/Flovent, Serevent
Seretide/Advair 1,793 1,779 963 963 664 650 166 166
Flixotide/Flovent 451 451 187 187 139 139 125 125
Serevent 264 264 102 102 122 122 40 40
Flixonase/Flonase 435 435 345 345 45 45 45 45
CENTRAL NERVOUS SYSTEM 2,626 2,626 1,735 1,735 565 565 326 326
Depression 1,408 1,408 987 987 196 196 225 225
Seroxat/Paxil 821 821 411 411 196 196 214 214
Wellbutrin 587 587 576 576 - - 11 11
Migraine 562 562 388 388 132 132 42 42
Imigran/Imitrex 505 505 362 362 107 107 36 36
Lamictal 496 496 301 301 161 161 34 34
Requip 84 84 38 38 41 41 5 5
ANTI-VIRALS 1,754 1,754 874 874 536 536 344 344
HIV 1,088 1,088 561 561 413 413 114 114
Combivir 424 424 210 210 166 166 48 48
Trizivir 247 247 139 139 98 98 10 10
Epivir 221 221 107 107 85 85 29 29
Ziagen 117 117 56 56 44 44 17 17
Agenerase, Lexiva 42 42 31 31 8 8 3 3
Herpes 535 535 285 285 103 103 147 147
Valtrex 425 425 277 277 67 67 81 81
Zovirax 110 110 8 8 36 36 66 66
Zeffix 96 96 8 8 16 16 72 72
ANTI-BACTERIALS 1,165 1,154 271 271 517 506 377 377
Augmentin 538 538 173 173 220 220 145 145
Zinnat/Ceftin 160 149 7 7 97 86 56 56
METABOLIC 929 927 634 634 98 96 197 197
Avandia, Avandamet 829 827 634 634 74 72 121 121
VACCINES 846 845 189 189 367 366 290 290
Hepatitis 297 296 100 100 145 144 52 52
Infanrix, Pediarix 257 257 89 89 114 114 54 54
ONCOLOGY AND EMESIS 705 705 514 514 128 128 63 63
Zofran 573 573 425 425 98 98 50 50
Hycamtin 75 75 49 49 21 21 5 5
CARDIOVASCULAR AND UROGENITAL 653 652 412 412 166 165 75 75
Coreg 317 317 311 311 - - 6 6
Levitra 37 37 15 15 15 15 7 7
Avodart 41 41 23 23 17 17 1 1
OTHER 739 735 67 67 219 216 453 452
Zantac 204 204 54 54 55 55 95 95
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 12,659 12,625 6,311 6,311 3,731 3,698 2,617 2,616
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Three months ended 31st December 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 1,173 1,167 568 568 403 397 202 202
Seretide/Advair, 920 914 458 458 328 322 134 134
Flixotide/Flovent, Serevent
Seretide/Advair 668 662 367 367 238 232 63 63
Flixotide/Flovent 167 167 64 64 50 50 53 53
Serevent 85 85 27 27 40 40 18 18
Flixonase/Flonase 143 143 105 105 14 14 24 24
CENTRAL NERVOUS SYSTEM 837 836 536 536 183 182 118 118
Depression 406 406 267 267 56 56 83 83
Seroxat/Paxil 242 242 108 108 55 55 79 79
Wellbutrin 164 164 159 159 1 1 4 4
Migraine 198 198 139 139 44 44 15 15
Imigran/Imitrex 177 177 130 130 35 35 12 12
Lamictal 182 181 113 113 58 57 11 11
Requip 32 32 15 15 15 15 2 2
ANTI-VIRALS 606 605 291 291 189 188 126 126
HIV 375 374 186 186 146 145 43 43
Combivir 147 146 70 70 60 59 17 17
Trizivir 75 75 38 38 32 32 5 5
Epivir 73 73 32 32 30 30 11 11
Ziagen 38 38 17 17 16 16 5 5
Agenerase, Lexiva 21 21 15 15 4 4 2 2
Herpes 183 183 95 95 35 35 53 53
Valtrex 146 146 92 92 23 23 31 31
Zovirax 37 37 3 3 12 12 22 22
Zeffix 34 34 3 3 6 6 25 25
ANTI-BACTERIALS 396 393 85 85 184 182 127 126
Augmentin 170 170 50 50 78 78 42 42
Zinnat/Ceftin 58 56 2 2 36 34 20 20
METABOLIC 324 324 218 218 37 37 69 69
Avandia, Avandamet 287 287 218 218 29 29 40 40
VACCINES 350 349 79 79 156 155 115 115
Hepatitis 109 109 34 34 56 56 19 19
Infanrix, Pediarix 100 99 40 40 48 47 12 12
ONCOLOGY AND EMESIS 229 229 165 165 42 42 22 22
Zofran 190 190 140 140 32 32 18 18
Hycamtin 24 24 15 15 8 8 1 1
CARDIOVASCULAR AND UROGENITAL 280 280 151 151 96 96 33 33
Coreg 115 115 114 114 - - 1 1
Levitra 12 12 5 5 6 6 1 1
Avodart 23 23 11 11 10 10 2 2
OTHER 292 292 21 21 107 107 164 164
Zantac 69 69 16 16 17 17 36 36
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 4,487 4,475 2,114 2,114 1,397 1,386 976 975
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Year ended 31st December 2004
Total USA Europe International
--------------- --------------- --------------- ---------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m £m £m
------- ----- ------- ----- ------- ----- ------- -----
RESPIRATORY 4,415 4,394 2,183 2,183 1,538 1,517 694 694
Seretide/Advair, 3,428 3,408 1,710 1,710 1,253 1,233 465 465
Flixotide/Flovent, Serevent
Seretide/Advair 2,461 2,441 1,330 1,330 902 882 229 229
Flixotide/Flovent 618 618 251 251 189 189 178 178
Serevent 349 349 129 129 162 162 58 58
Flixonase/Flonase 578 578 450 450 59 59 69 69
CENTRAL NERVOUS SYSTEM 3,463 3,462 2,271 2,271 748 747 444 444
Depression 1,814 1,814 1,254 1,254 252 252 308 308
Seroxat/Paxil 1,063 1,063 519 519 251 251 293 293
Wellbutrin 751 751 735 735 1 1 15 15
Migraine 760 760 527 527 176 176 57 57
Imigran/Imitrex 682 682 492 492 142 142 48 48
Lamictal 678 677 414 414 219 218 45 45
Requip 116 116 53 53 56 56 7 7
ANTI-VIRALS 2,360 2,359 1,165 1,165 725 724 470 470
HIV 1,463 1,462 747 747 559 558 157 157
Combivir 571 570 280 280 226 225 65 65
Trizivir 322 322 177 177 130 130 15 15
Epivir 294 294 139 139 115 115 40 40
Ziagen 155 155 73 73 60 60 22 22
Agenerase, Lexiva 63 63 46 46 12 12 5 5
Herpes 718 718 380 380 138 138 200 200
Valtrex 571 571 369 369 90 90 112 112
Zovirax 147 147 11 11 48 48 88 88
Zeffix 130 130 11 11 22 22 97 97
ANTI-BACTERIALS 1,561 1,547 356 356 701 688 504 503
Augmentin 708 708 223 223 298 298 187 187
Zinnat/Ceftin 218 205 9 9 133 120 76 76
METABOLIC 1,253 1,251 852 852 135 133 266 266
Avandia, Avandamet 1,116 1,114 852 852 103 101 161 161
VACCINES 1,196 1,194 268 268 523 521 405 405
Hepatitis 406 405 134 134 201 200 71 71
Infanrix, Pediarix 357 356 129 129 162 161 66 66
ONCOLOGY AND EMESIS 934 934 679 679 170 170 85 85
Zofran 763 763 565 565 130 130 68 68
Hycamtin 99 99 64 64 29 29 6 6
CARDIOVASCULAR AND UROGENITAL 933 932 563 563 262 261 108 108
Coreg 432 432 425 425 - - 7 7
Levitra 49 49 20 20 21 21 8 8
Avodart 64 64 34 34 27 27 3 3
OTHER 1,031 1,027 88 88 326 323 617 616
Zantac 273 273 70 70 72 72 131 131
-------------- -------------- ------------- -------------
TOTAL PHARMACEUTICALS 17,146 17,100 8,425 8,425 5,128 5,084 3,593 3,591
-------------- -------------- ------------- -------------
Turnover includes co-promotion income.
CONSUMER HEALTHCARE TURNOVER
Year ended 31st December 2003
UK GAAP IFRS
£m £m
-------- --------
Over-the-counter medicines 1,556 1,472
Analgesics 342 328
Dermatological 237 225
Gastrointestinal 283 267
Respiratory tract 151 144
Smoking control 325 315
Natural wellness support 166 148
Other 52 45
Oral care 1,082 915
Nutritional healthcare 622 569
-------- --------
Total 3,260 2,956
-------- --------
CONSUMER HEALTHCARE TURNOVER
2004
Three months ended Three months ended Six months ended
31st March 2004 30th June 2004 30th June 2004
-------------------- -------------------- -------------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m
-------- -------- -------- -------- -------- --------
Over-the-counter medicines 353 332 357 335 710 667
Analgesics 85 81 89 85 174 166
Dermatological 45 42 53 50 98 92
Gastrointestinal 63 59 63 59 126 118
Respiratory tract 35 34 26 25 61 59
Smoking control 77 73 78 74 155 147
Natural wellness support 38 34 37 32 75 66
Other 10 9 11 10 21 19
Oral care 260 220 267 226 527 446
Nutritional healthcare 150 135 174 155 324 290
-------- -------- -------- -------- -------- --------
Total 763 687 798 716 1,561 1,403
-------- -------- -------- -------- -------- --------
CONSUMER HEALTHCARE TURNOVER
2004
Three months ended Nine months ended Three months ended
30th September 2004 30th September 2004 31st December 2004
-------------------- -------------------- -------------------
UK GAAP IFRS UK GAAP IFRS UK GAAP IFRS
£m £m £m £m £m £m
-------- -------- -------- -------- -------- --------
Over-the-counter medicines 364 342 1,074 1,009 415 391
Analgesics 87 84 261 250 88 83
Dermatological 47 43 145 135 48 45
Gastrointestinal 63 59 189 177 67 64
Respiratory tract 39 37 100 96 52 49
Smoking control 79 76 234 223 107 104
Natural wellness support 38 33 113 99 43 37
Other 11 10 32 29 10 9
Oral care 278 233 805 679 283 234
Nutritional healthcare 164 147 488 437 148 136
-------- -------- -------- -------- -------- --------
Total 806 722 2,367 2,125 846 761
-------- -------- -------- -------- -------- --------
CONSUMER HEALTHCARE TURNOVER
Year ended 31st December 2004
UK GAAP IFRS
£m £m
-------- --------
Over-the-counter medicines 1,489 1,400
Analgesics 349 333
Dermatological 193 180
Gastrointestinal 256 241
Respiratory tract 152 145
Smoking control 341 327
Natural wellness support 156 136
Other 42 38
Oral care 1,088 913
Nutritional healthcare 636 573
-------- --------
Total 3,213 2,886
-------- --------
End of Part 1
This information is provided by RNS
The company news service from the London Stock Exchange
Latest directors dealings
- 12 hours ago Savannah Energy
- 13 hours ago Buccaneer Energy PLC
- 13 hours ago Savannah Energy
- 13 hours ago Carclo
- 13 hours ago Schroder Japan Growth Fund